EyePoint Inc. (EYPT) is a Biotechnology: Laboratory Analytical Instruments company listed on NASDAQ. In the last 30 days Quantisnow tracked 11 wire items for EYPT, including 4 analyst ratings, 3 press releases and news items and 2 SEC filings. The most recent was published Oct 27, 2026.
Price$0.37+0.02 (+5.67%)
02:30 PM08:45 PM
News · 26 weeks45+400%
2026-05-102026-11-01
Mix2990d
- Analyst9(31%)
- SEC Filings7(24%)
- Other7(24%)
- Earnings3(10%)
- Insider2(7%)
- Market1(3%)
Latest news
25 items- SECSEC Form SCHEDULE 13G filed by EyePoint Inc.SCHEDULE 13G - EyePoint, Inc. (0001314102) (Subject)
- NEWSEYPT Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into EyePoint Pharmaceuticals (EYPT)NEW YORK CITY, NY / ACCESS Newswire / October 21, 2026 / EyePoint Pharmaceuticals (NASDAQ:EYPT) shares fell roughly 80% after the Company reported that its Phase 3 LUCIA trial of DURAVYU in wet age-related macular degeneration missed its primary endpoint of non-inferiority to on-label aflibercept. If you held EYPT shares when that result hit, your losses may be part of an active investigation. Investors who suffered losses are encouraged to submit their EYPT loss information now. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.In LUCIA, DURAVYU patients gained approximately 2.5 letters in mean best-corrected visual acuity. Pati
- ANALYSTEyePoint downgraded by AnalystAnalyst downgraded EyePoint from Neutral to Underweight
- ANALYSTEyePoint downgraded by Mizuho with a new price targetMizuho downgraded EyePoint from Outperform to Neutral and set a new price target of $0.50
- ANALYSTEyePoint downgraded by GuggenheimGuggenheim downgraded EyePoint from Buy to Neutral
- PREyePoint Announces Strategic PrioritizationWATERTOWN, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced a strategic prioritization designed to reduce operating expenses and focus resources on its late-stage program for DURAVYU™ in diabetic macular edema (DME). This strategic realignment follows today’s topline readout from the Phase 3 LUCIA study of DURAVYU in wet AMD, which did not meet its primary endpoint of non-inferiority, despite vision improvements, and despite meeting key secondary endpoints including reduction in treatment burden, supplement-free
- PREyePoint Announces Topline Results from LUCIA, the Second Pivotal Phase 3 Clinical Trial of DURAVYU™ in Wet AMD– LUCIA did not achieve the primary endpoint of statistical non-inferiority in mean change in BCVA versus on-label aflibercept control, despite demonstrating visual improvement – – Key secondary endpoints in LUCIA were met including a superior 38% reduction in treatment burden (nominal p-value <0.0001), with 52% of eyes supplement-free and 71% receiving zero or one supplement up to Week 56, as well as strong anatomic control – – Continued favorable safety profile for DURAVYU with redosing – ─ DME program remains on track with pivotal Phase 3 topline data from two identical clinical trials anticipated in Q4 2027 – – Conference call to discuss the results to be held today at 8:00 a.m. EDT
- ANALYSTEyePoint downgraded by Jefferies with a new price targetJefferies downgraded EyePoint from Buy to Hold and set a new price target of $1.00
- SECSEC Form 8-K filed by EyePoint Inc.8-K - EyePoint, Inc. (0001314102) (Filer)
- SECSEC Form 8-K filed by EyePoint Inc.8-K - EyePoint, Inc. (0001314102) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by EyePoint Inc.SCHEDULE 13G/A - EyePoint, Inc. (0001314102) (Subject)
- PREyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)WATERTOWN, Mass., Sept. 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employee as inducement award outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 3,000 shares of EyePoint common stock to one new employee. The stock options were granted on September 15, 2026. The grant was approved by the Compensation Committee and made as an inducement material t
- SECEyePoint Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - EyePoint, Inc. (0001314102) (Filer)
- SECSEC Form SCHEDULE 13G filed by EyePoint Inc.SCHEDULE 13G - EyePoint, Inc. (0001314102) (Subject)
- ANALYSTEyePoint downgraded by TD Cowen with a new price targetTD Cowen downgraded EyePoint from Buy to Hold and set a new price target of $4.00
- PREyePoint Announces Participation at Upcoming Investor Conferences and Scientific MeetingWATERTOWN, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that the Company will participate at the following upcoming conferences: Citi 2026 Biopharma Back to School ConferenceForum: Fireside ChatDate: September 9, 2026Time: 8:00 am ETCantor Global Healthcare Conference 2026Forum: Fireside ChatDate: September 10, 2026Time: 10:20 am ETMorgan Stanley Global Healthcare Conference Forum: Fireside ChatDate: September 15, 2026Time: 7:00 am ET A webcast and subsequent archived replay of each fireside chat a
- INSIDERChief Financial Officer Elston George acquired 5,000 shares, gifted 64,953 shares, received a gift of 64,953 shares and disposed of 5,000 shares, decreasing direct ownership by 65% to 32,517 units (SEC Form 4)4 - EyePoint, Inc. (0001314102) (Issuer)
- INSIDERDirector Zaderej Karen L. bought $52,258 worth of shares (10,600 units at $4.93), increasing direct ownership by 28% to 49,100 units (SEC Form 4)4 - EyePoint, Inc. (0001314102) (Issuer)
- ANALYSTEyePoint downgraded by Chardan Capital Markets with a new price targetChardan Capital Markets downgraded EyePoint from Buy to Neutral and set a new price target of $5.00
- ANALYSTEyePoint downgraded by RBC Capital Mkts with a new price targetRBC Capital Mkts downgraded EyePoint from Outperform to Sector Perform and set a new price target of $5.00
- ANALYSTEyePoint downgraded by H.C. WainwrightH.C. Wainwright downgraded EyePoint from Buy to Neutral
- ANALYSTEyePoint downgraded by Cantor FitzgeraldCantor Fitzgerald downgraded EyePoint from Overweight to Neutral
- SECEyePoint Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - EyePoint, Inc. (0001314102) (Filer)
- PREyePoint Announces Topline Data from LUGANO, the First of Two Pivotal Phase 3 Clinical Trials for DURAVYU™ 2.7mg in Wet AMD– DURAVYU was non-inferior to on-label aflibercept control (nominal p-value = 0.0096) in an ad hoc analysis excluding a 4% asymmetric cohort (9 of 211 patients) who experienced vision loss (≥ 15 letters) unrelated to wet AMD; primary endpoint not achieved in full dataset, confounded by this asymmetric cohort – – LUGANO demonstrated clinically meaningful results that reinforce DURAVYU’s potential to improve the treatment paradigm in wet AMD, with compelling key secondary endpoints, including reduction in treatment burden, supplement-free rates, favorable safety profile with redosing, and strong anatomic control through Week 56 compared to on-label aflibercept – – 42% reduction in treatment
- PREyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)WATERTOWN, Mass., Aug. 14, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 14,600 shares of EyePoint common stock to two new employees. The stock options were granted on August 14, 2026. The grants were approved by the Compensation Committee and made as an inducement material
EYPT FAQ
7 questionsWhat does EyePoint Inc. do?
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation...What is the latest news on EYPT?
In the last 30 days Quantisnow tracked 11 wire items for EYPT: 4 analyst ratings, 3 press releases and news items, 2 SEC filings and 1 earnings update. The most recent was published on October 27, 2026.Where does EYPT stock trade?
EyePoint Inc. (EYPT) is listed on NASDAQ.What sector and industry is EYPT in?
EyePoint Inc. operates in the Industrials sector, Biotechnology: Laboratory Analytical Instruments industry.What are analysts saying about EYPT?
Across the last 8 analyst actions on EyePoint Inc., there were 0 upgrades and 8 downgrades. The most recent action was from Analyst: Underweight on 2026-10-20.What companies are similar to EYPT?
Notable peers in the same industry include A (Agilent Technologies Inc.), WAT (Waters Corporation), MTD (Mettler-Toledo International Inc.), RVTY (Revvity Inc.), AVTR (Avantor Inc.). Compare EYPT side-by-side with any of them on Quantisnow.How can I track EYPT on Quantisnow?
Quantisnow aggregates EyePoint Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow EYPT to receive live email and push alerts on every new disclosure.